

Ifw



PATENT
ATTORNEY DOCKET NO. 50304/114001

Certificate of Mailing: Date of Deposit: May 26, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan M. Cannon
Printed name of person mailing correspondence

Susan M Cannon
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: WAER et al. Art Unit: Not yet assigned
Serial No.: 10/595,161 Examiner: Not yet assigned
Filed: March 10, 2006 Customer No.: 21559
Title: PTERIDINE DERIVATIVES FOR THE TREATMENT OF SEPTIC SHOCK
AND TNF- α -RELATED DISEASES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents. Copies of communications from the International Searching Authority issued in connection with a counterpart application are also enclosed.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the merits.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 26 May 2006



James D. DeCamp, Ph.D.
Reg. No. 43,580

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



<p>SUBSTITUTE FORM PTO-1449 (MODIFIED)</p> <p style="text-align: center;">U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	<p>Attorney Docket No. 50304/114001</p> <p>Serial No. 10/595,161</p> <p>Applicant WAER et al.</p> <p>Filing Date March 10, 2006</p> <p>Group Not yet assigned</p> <p>IDS Filed May 26, 2006</p> <p>Customer No. 21559</p>
---	---

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	3,122,546	02/25/64	Osdene			
	5,047,405	09/10/91	Gennari			
	5,300,509	04/05/94	Block et al.			
	5,500,428	03/19/96	Block et al.			
	5,929,046	07/27/99	McMurry et al.			
	6,043,228	03/28/00	McMurry et al.			
	2004/077859A1	04/22/04	Albert Waer et al.			
	2004/102447 A1	05/27/04	Bonnert et al.			
	6,844,343B1	01/18/05	Pfleiderer et al.			
	2005/054653A1	03/10/05	Eisenbrand et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	DD 267 495 A1	05/03/89	Germany			No
	EP 0 290 819	04/18/88	EPO			
	EP 0 362 645	09/23/89	EPO			
	EP 0 544 445	11/19/92	EPO			
	WO 00/39129	07/06/00	WIPO			
	WO 01/21619	03/29/01	WIPO			Abstract Only
	WO 02/32507	04/25/02	WIPO			
	WO 03/062240	07/31/03	WIPO			Abstract Only

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/114001
	Serial No.	10/595,161
	Applicant	WAER et al.
	Filing Date	March 10, 2006
	Group	Not yet assigned
	IDS Filed	May 26, 2006
	Customer No.	21559

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories: Whitehouse Station, N.J., <i>Leukemias, Chapt. 138:953-954</i> (1999).
	Beers et al. (eds.), The Merck Manual of Diagnosis and Therapy, Merck Research Laboratories: Whitehouse Station, N.J., <i>Neurologic Disorders, Sec. 14:1474-1476</i> (1999).
	Fröhlich et al., "Inhibition of Neuronal Nitric Oxide Synthase by 4-Amino Pteridine Derivatives: Structure-Activity Relationship of Antagonists of (6R)-5,6,7,8-Tetrahydrobiopterin Cofactor," <i>J. Med. Chem.</i> 42:4108-4121 (1999).
	Landry and Gies, <i>Pharmacologie. Des Cibles Vers L'Indication Thérapeutique: Cours et Exercices, Dunod: Paris</i> , p.177 (2003).
	Matter et al., "Structural Requirements for Inhibition of the Neuronal Nitric Oxide Synthase (NOS-I): 3D-QSAR Analysis of 4-Oxo- and 4-Amino-Pteridine-Based Inhibitors," <i>J. Med. Chem.</i> 45:2923-2941 (2002).
	Moreb and Zucali, "The Therapeutic Potential of Interleukin-1 and Tumor Necrosis Factor on Hematopoietic Stem Cells," <i>Leuk. Lymphoma</i> 8:267-275 (1992) (Abstract Only).
	Nicolaus, "Symbiotic Approach to Drug Design," in <i>Decision Making in Drug Research</i> , Gross (ed.), Raven Press: New York, p.173-186 (1983).
	PCT International Search Report (PCT/EP2004/010198) (mailed 26 April 2005).
	PCT Written Opinion of the International Preliminary Examining Authority (PCT/EP2004/010198) (mailed 01 September 2005).
	PCT Written Opinion of the International Searching Authority (PCT/EP2004/010198).
	Response to the Written Opinion (PCT/EP2004/010198) (mailed 28 October 2005).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	